Table 2.
Patient characteristics by creatinine clearance and rivaroxaban doses in the unmatched and propensity score matched cohorts
| Unmatched cohort | Propensity Score Matched cohort | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Normal renal function group (CrCl ≥ 50 mL/min) |
Renal dysfunction group (CrCl < 50 mL/min) |
Normal renal function group (CrCl ≥ 50 mL/min) |
Renal dysfunction group (CrCl < 50 mL/min) |
|||||||||
| 10 mg/day | 15 mg/day | P value† | 10 mg/day | 15 mg/day | P value† | 10 mg/day | 15 mg/day | P value† | 10 mg/day | 15 mg/day | P value† | |
| (n = 1609) | (n = 3717) | (n = 1372) | (n = 108) | (n = 1314) | (n = 1314) | (n = 108) | (n = 108) | |||||
| Sex (male), n (%) | 1025 (63.7) | 2813 (75.7) | < 0.001 | 711 (51.8) | 56 (51.9) | 0.995 | 886 (67.4) | 874 (66.5) | 0.619 | 60 (55.6) | 56 (51.9) | 0.585 |
| Age (years), mean ± SD | 73.8 ± 7.8 | 67.4 ± 8.6 | < 0.001 | 80.0 ± 6.1 | 77.0 ± 6.0 | < 0.001 | 72.6 ± 7.3 | 72.6 ± 6.6 | 0.898 | 77.9 ± 6.0 | 77.0 ± 6.0 | 0.258 |
| Age ≥ 75 years, n (%) | 829 (51.5) | 767 (20.6) | < 0.001 | 1147 (83.6) | 76 (70.4) | < 0.001 | 570 (43.4) | 567 (43.2) | 0.906 | 75 (69.4) | 76 (70.4) | 0.882 |
| Body weight (kg), mean ± SD | 62.8 ± 10.9 | 66.6 ± 12.0 | < 0.001 | 52.9 ± 9.6 | 52.4 ± 7.9 | 0.223 | 63.2 ± 10.9 | 63.4 ± 11.0 | 0.631 | 53.0 ± 8.0 | 52.4 ± 7.9 | 0.620 |
| CHADS2 score, mean ± SD | 2.2 ± 1.3 | 1.8 ± 1.2 | < 0.001 | 2.8 ± 1.3 | 2.6 ± 1.3 | 0.147 | 2.1 ± 1.3 | 2.1 ± 1.3 | 0.867 | 2.4 ± 1.3 | 2.6 ± 1.3 | 0.311 |
| < 2 points, n (%) | 521 (32.4) | 1758 (47.3) | < 0.001 | 198 (14.4) | 21 (19.4) | 0.055 | 493 (37.5) | 455 (34.6) | 0.339 | 27 (25.0) | 21 (19.4) | 0.602 |
| 2 points, n (%) | 496 (30.8) | 1014 (27.3) | – | 441 (32.1) | 39 (36.1) | – | 385 (29.3) | 421 (32.0) | - | 34 (31.5) | 39 (36.1) | – |
| ≥ 3 points, n (%) | 592 (36.8) | 945 (25.4) | – | 733 (53.4) | 48 (44.4) | – | 436 (33.2) | 438 (33.3) | - | 47 (43.5) | 48 (44.4) | – |
| CHA2DS2-VASc score, mean ± SD | 3.7 ± 1.6 | 2.8 ± 1.6 | < 0.001 | 4.5 ± 1.5 | 4.3 ± 1.5 | 0.169 | 3.5 ± 1.5 | 3.5 ± 1.5 | 0.604 | 4.0 ± 1.3 | 4.3 ± 1.5 | 0.172 |
| HAS-BLED score, mean ± SD | 1.5 ± 0.9 | 1.3 ± 0.9 | < 0.001 | 1.6 ± 0.8 | 1.5 ± 0.8 | 0.298 | 1.5 ± 0.9 | 1.5 ± 0.9 | 0.400 | 1.7 ± 0.8 | 1.5 ± 0.8 | 0.191 |
| Comorbidity and medical history, n (%) | ||||||||||||
| Congestive heart failure | 449 (27.9) | 760 (20.4) | < 0.001 | 560 (40.8) | 37 (34.3) | 0.181 | 335 (25.5) | 345 (26.3) | 0.656 | 36 (33.3) | 37 (34.3) | 0.886 |
| Hypertension | 1213 (75.4) | 2530 (68.1) | < 0.001 | 1017 (74.1) | 83 (76.9) | 0.532 | 965 (73.4) | 974 (74.1) | 0.690 | 76 (70.4) | 83 (76.9) | 0.280 |
| Diabetes mellitus | 406 (25.2) | 917 (24.7) | 0.663 | 332 (24.2) | 24 (22.2) | 0.644 | 323 (24.6) | 334 (25.4) | 0.620 | 18 (16.7) | 24 (22.2) | 0.302 |
| Angina pectoris | 239 (14.9) | 343 (9.2) | < 0.001 | 209 (15.2) | 12 (11.1) | 0.247 | 170 (12.9) | 159 (12.1) | 0.517 | 14 (13.0) | 12 (11.1) | 0.676 |
| Dyslipidemia | 704 (43.8) | 1566 (42.1) | 0.271 | 552 (40.2) | 42 (38.9) | 0.784 | 565 (43.0) | 563 (42.8) | 0.937 | 42 (38.9) | 42 (38.9) | 1.000 |
| Stroke (ischemic/hemorrhagic) | 306 (19.0) | 762 (20.5) | 0.215 | 363 (26.5) | 28 (25.9) | 0.904 | 252 (19.2) | 245 (18.6) | 0.727 | 28 (25.9) | 28 (25.9) | 1.000 |
| Ischemic stroke | 285 (17.7) | 716 (19.3) | 0.184 | 347 (25.3) | 25 (23.1) | 0.621 | 231 (17.6) | 221 (16.8) | 0.605 | 26 (24.1) | 25 (23.1) | 0.873 |
| Hemorrhagic stroke | 28 (1.7) | 70 (1.9) | 0.721 | 28 (2.0) | 4 (3.7) | 0.253 | 28 (2.1) | 30 (2.3) | 0.791 | 2 (1.9) | 4 (3.7) | 0.408 |
| Transient ischemic attack | 58 (3.6) | 94 (2.5) | 0.030 | 48 (3.5) | 6 (5.6) | 0.272 | 47 (3.6) | 43 (3.3) | 0.668 | 5 (4.6) | 6 (5.6) | 0.757 |
| Systemic embolism | 12 (0.7) | 31 (0.8) | 0.741 | 14 (1.0) | 1 (0.9) | 0.925 | 11 (0.8) | 7 (0.5) | 0.344 | 0 (0.0) | 1 (0.9) | 1.000 |
| Myocardial infarction | 84 (5.2) | 115 (3.1) | < 0.001 | 81 (5.9) | 5 (4.6) | 0.586 | 58 (4.4) | 57 (4.3) | 0.924 | 1 (0.9) | 5 (4.6) | 0.098 |
| Malignant tumor | 157 (9.8) | 289 (7.8) | 0.017 | 162 (11.8) | 17 (15.7) | 0.227 | 128 (9.7) | 124 (9.4) | 0.791 | 11 (10.2) | 17 (15.7) | 0.224 |
| Bleeding and/or bleeding tendency | 82 (5.1) | 136 (3.7) | 0.015 | 55 (4.0) | 3 (2.8) | 0.526 | 57 (4.3) | 64 (4.9) | 0.515 | 7 (6.5) | 3 (2.8) | 0.195 |
| Non-PAF (persistent/permanent), n (%) | 889 (55.3) | 2033 (54.7) | 0.708 | 803 (58.5) | 58 (53.7) | 0.328 | 739 (56.2) | 732 (55.7) | 0.783 | 55 (50.9) | 58 (53.7) | 0.683 |
| Use of concomitant antiplatelet, n (%) | 284 (17.7) | 443 (11.9) | < 0.001 | 246 (17.9) | 17 (15.7) | 0.567 | 210 (16.0) | 213 (16.2) | 0.874 | 20 (18.5) | 17 (15.7) | 0.588 |
CrCl creatinine clearance, PAF paroxysmal atrial fibrillation, SD standard deviation
†10 mg/day vs. 15 mg/day